| | 150683-30-0 Basic information More.. |
| Product Name: | Tolvaptan | | Synonyms: | N-[4-(9-chloro-6-hydroxy-2-azabicyclo[5.4.0]undeca-8,10,12-triene-2-carbonyl)-3-methyl-phenyl]-2-methyl-benzamide;Tolvaptan;N-[4-[(5R)-7-Chloro-5-hydroxy-2,3,4,5-tetrahydro-1-benzazepine-1-carbonyl]-3-methylphenyl]-2-methylbenzamide;N-(4-{[(5R)-7-chloro-5-hydroxy-2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl]carbonyl}-3-Methylphenyl)-2-MethylbenzaMide;OPC 41061;OPC-41061;SaMsca;Tolvaptan Tablets | | CAS: | 150683-30-0 | | MF: | C26H25ClN2O3 | | MW: | 448.94 | | EINECS: | 691-537-5 | | Mol File: | 150683-30-0.mol |  |
Use
Tolvaptan(SAMSCA) should be initiated and re-initiated in patients only in a hospital where serum sodium can be monitored closely. Too rapid correction of hyponatremia (e.g., 12 mEq/L/24 hours) can cause osmotic demyelination resulting in dysarthria, mutism, dysphagia, lethargy, affective changes, spastic quadriparesis, seizures, coma and death. In susceptible patients, including those with severe malnutrition, alcoholism or advanced liver disease, slower rates of correction may be advisable.
Tolvaptan(SAMSCA) is contraindicated in the following conditions:
Urgent need to raise serum sodium acutely
Inability of the patient to sense or appropriately respond to thirst
Hypovolemic hyponatremia
Concomitant use of strong CYP 3A inhibitors
Anuric patients
Hypersensitivity (e.g. anaphylactic shock, rash generalized) to tolvaptan or its components
- Tolvaptan
-
- US $0.00-0.00 / kg
- 2024-04-26
- CAS:150683-30-0
- Min. Order: 1kg
- Purity: 99.5%
- Supply Ability: 5000
- Tolvaptan
-
- US $30.00-10.00 / kg
- 2024-04-26
- CAS:150683-30-0
- Min. Order: 1kg
- Purity: 99%
- Supply Ability: 300tons
- Tolvaptan
-
- US $2.00 / g
- 2024-04-26
- CAS:150683-30-0
- Min. Order: 1g
- Purity: 99%
- Supply Ability: 300tons
|
|
150683-30-0
Recommend Suppliers |
|